The Phase IIb trial, whose kickoff has been long-anticipated, is designed to study the influence of psilocybin in mitigating the symptoms and effects of Adjustment Disorder following severe cancer diagnoses in the palliative care space.
To bolster its efforts in delivering effective, controlled settings for these clinical trials, Psyence has strategically partnered with Fluence and iNGEN CRO Pty Ltd, through its Australian subsidiary, Psyence Australia Pty Ltd. The collaboration is structured to ensure that the clinical trials are methodically conducted, enabling the study of potential effects of psilocybin-assisted psychotherapy (PAP) for Adjustment Disorder following a recent cancer diagnosis towards enhancing palliative care.
Fluence has established an international reputation as a leader in the professional education and training arena for psychedelic therapy research. iNGen is a reputable Australian clinical research organization, providing the necessary infrastructure critical to the clinical trials.
This announcement comes on the heels of a promising report published in the journal, Molecular Psychiatry, that suggests nature-derived psilocybin could inherently be significantly more therapeutic than its synthetic counterparts.
Psyence Biomed, which has been spearheading the cultivation of nature-derived psilocybin, understandably welcomes these findings. The Company has remained committed to innovative research into the therapeutic potential of psychedelic compounds, especially in the management of mental health disorders.
With the setup and partnerships in place, as well as encouraging insights from recent scientific findings, Psyence Biomed has amplified confidence in the forthcoming Phase IIb trials. The cutting-edge research could potentially prove revolutionary in the therapeutic management of Adjustment Disorder, particularly in the context of palliative care, thus reshaping the trajectory of mental health care overall.
Comments